InvestSMART

Cochlear Limited (ASX: COH) - Announcements

Current share price for COH : $133.600 0.33 (0.25%)+

ASX company news and announcements for Cochlear Limited (COH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cochlear Limited (COH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cochlear Limited (COH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cochlear Limited (COH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8,737 COCHLEAR TO LAUNCH NUCLEUS PROFILE IMPLANT SERIES IN EUROP 2 Jun 2014 8:28AM $61.500 $133.600 risen by 117.24%
$8,737 FDA approves Cochlear Nucleus Hybrid for sale in USA 21 Mar 2014 8:52AM $58.960 $133.600 risen by 126.59%
$8,737 Half Year Report & Accounts 11 Feb 2014 9:00AM $53.680 $133.600 risen by 148.88%
$8,737 COH Jury Trial Verdict on USA Patent Infringement Case 24 Jan 2014 1:10PM $57.850 $133.600 risen by 130.94%
$8,737 Hybrid Hearing Device Update 11 Nov 2013 9:14AM $57.140 $133.600 risen by 133.81%
$8,737 15/10/13 Chairmans AGM Address to Shareholders 15 Oct 2013 9:46AM $58.760 $133.600 risen by 127.37%
$8,737 Full Year Statutory Accounts 6 Aug 2013 10:01AM $60.000 $133.600 risen by 122.67%
$8,737 Cochlear Limited Market Update 3 Jun 2013 8:28AM $52.880 $133.600 risen by 152.65%
$8,737 Half Yearly Report and Accounts 5 Feb 2013 10:04AM $72.960 $133.600 risen by 83.11%
$8,737 COH Update on Nucleus CI500 series implant recall 7 Aug 2012 9:58AM $63.000 $133.600 risen by 112.06%
$8,737 Appendix 4E and Full Year Statutory Accounts 7 Aug 2012 9:58AM $63.000 $133.600 risen by 112.06%
$8,737 COH Clinic Update Letter 7 Feb 2012 9:26AM $62.520 $133.600 risen by 113.69%
$8,737 Half Yearly Report and Accounts 7 Feb 2012 9:22AM $62.520 $133.600 risen by 113.69%
$8,737 18/10/11 Chairman`s AGM Address to Shareholders 18 Oct 2011 10:00AM $53.540 $133.600 risen by 149.53%
$8,737 Cochlear Voluntary Recall 12 Sep 2011 8:23AM $57.090 $133.600 risen by 134.02%
$8,737 Preliminary Final Report Appendix 4E 9 Aug 2011 9:58AM $65.000 $133.600 risen by 105.54%
$8,737 Half Year Report and Accounts 8 Feb 2011 9:39AM $76.180 $133.600 risen by 75.37%
$8,737 COH - F10 Preliminary Final Report - Appendix 4E 10 Aug 2010 9:05AM $69.860 $133.600 risen by 91.24%
$8,737 Settlement Agreement with the DOJ and OIG 4 Jun 2010 9:46AM $74.820 $133.600 risen by 78.56%
$8,737 Response to ASX Price Query 26 Mar 2010 2:06PM $72.480 $133.600 risen by 84.33%
$8,737 COH Half Year Report as at 31 December 2009 09.02.10 9 Feb 2010 9:25AM $63.550 $133.600 risen by 110.23%
$8,737 Technnology Purchase Towards a Totally Implantable Cochlear 9 Sep 2009 8:44AM $60.400 $133.600 risen by 121.19%
$8,737 FDA Approval for Nucleus 5 System 4 Sep 2009 1:49PM $61.170 $133.600 risen by 118.41%
$8,737 Full Year Statutory Accounts 11 Aug 2009 9:00AM $58.660 $133.600 risen by 127.75%
$8,737 COH Market Update 14th July 2009 14 Jul 2009 9:22AM $51.970 $133.600 risen by 157.07%

851 - 875 of 900 results

Page 35 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.